BLOG ARTICLE
Pharmacokinetics and Pharmacodynamics: Turning Data Into Clinical Insight
The drug was approved in the EU and US. The dosage of 0.3 mg/kg was approved and listed on the label.
An investigational drug was in Phase 3 to treat a rare genetic disease disorder. The number of subjects participating in the Phase 3 study was limited. Phase 3 study demonstrated clinically significant efficacy and favorable safety. The client is preparing for an NDA. Although 0.3 mg/kg was used for all patients, it was unknown whether this dose could be justified in the NDA submission.
XP Pharma proposed an analysis plan. We divided patients into four quartiles based on pharmacokinetic (PK) exposures. The efficacy endpoint was analyzed for each quartile. We found that efficacy was comparable across the 4 PK-exposure quartiles, indicating that the PK exposures at 0.3 mg/kg reached the plateau of the dose-response curve. Likewise, the frequency of adverse events (AEs) did not increase with increasing PK exposure to the drug, indicating that the incidence of these AEs was independent of the PK concentrations of the three analytes. The analysis results were included in the CTD 2.7.2 summary of Clinical Pharmacology for NDA and other CTD modules.
Protocol design, PK/PD integration, and study oversight for various types of clinical pharmacology studies
End-to-end support for NCA PK analysis, results interpretation, and submission-ready reports
End-to-end PK/PD modeling support to enable model-informed drug development (MIDD) across all phases
End-to-end strategy development and regulatory writing for IND/NDA/BLA submissions.
Pharmacokinetics and Pharmacodynamics: Turning Data Into Clinical Insight
©Copyright 2019 to 2026. All Rights Reserved
